Additional information
| Active substance | Tirzepatide |
|---|---|
| Active Half-Life | 5 days |
| Classification | Dual GIP and GLP-1 Receptor Agonist |
| Hepatotoxicity | No significant hepatotoxicity reported |
| Lab Test | Monitoring blood glucose levels and HbA1c |
| Also known as | LY3298176 |
| WAREHOUSE | International Warehouse 3 |
| Blood pressure | May reduce blood pressure |
| Trade name | Mounjaro |
| Storage conditions | Store in a refrigerator at 2В°C to 8В°C (36В°F to 46В°F), protect from light |
| Chemical name | Tirzepatide |
| Formula | C225H348N48O68 |
| Substance class | Glucagon-like peptide-1 (GLP-1) receptor agonists |
| Main action | Lowers blood glucose levels |
| Half-life | Approximately 5 days |
| Dosage (medical) | Typically started at 2.5 mg once weekly, can be increased to 5 mg, 10 mg, or 15 mg once weekly depending on response and tolerability |
| Dosage (sports) | Not applicable as it is not used for performance enhancement |
| Effects | Improves glycemic control, promotes weight loss |
| Side effects | Nausea, diarrhea, decreased appetite, vomiting, constipation |
| Use in sports | None, not used for performance enhancement |
| Manufacturer | Nakon Medical |
Champix 56 tabs Pfizer
Norvacs 10 mg Pfizer
Prograf 1mg Astellas Pharma
Avory Pharma Winstrol 10mg 100 Kapseln
Balkan Pharma Nandrolon Deca 200mg 10ml
Seretide Disckus (Advair) 250 mcg Glaxosmithkline
T3bolic Cooper Pharma
GLUCOPHAGE Merckgroup 

Reviews
There are no reviews yet.